Lantheus Reports Q4 & FY25 Results, Lowers FY26 EPS Guidance, Shifts Strategic Focus
Summary
Lantheus reported Q4 and FY25 financial results, announced a strategic shift to radiodiagnostics, and provided significantly lower adjusted EPS guidance for FY26 compared to FY25 actuals.
Key Events
-
Q4 and Full Year 2025 Financial Results
Reported Q4 2025 worldwide revenue of $406.8 million (+4.0% YoY) and adjusted diluted EPS of $1.67 (+4.7% YoY). Full year 2025 worldwide revenue was $1.54 billion (+0.5% YoY) and adjusted diluted EPS was $6.08 (-10.0% YoY). Sales of PYLARIFY decreased 9.7% in Q4.
-
Lowered Full Year 2026 Adjusted EPS Guidance
Provided full year 2026 adjusted diluted EPS guidance of $5.00 - $5.25, a notable decrease from the $6.08 achieved in full year 2025. Full year 2026 revenue guidance is $1.4 billion - $1.45 billion, also lower than FY25 actuals.
-
Strategic Focus Shift Announced
The company is sharpening its strategic focus to innovative radiodiagnostics and will pursue value-maximizing alternatives for its radiotherapeutic assets. This follows the completed divestiture of its legacy SPECT business.
-
Significant Share Repurchase
Repurchased $100 million of common stock in the fourth quarter of 2025, pursuant to a previously announced plan.
Analysis
Lantheus Holdings reported mixed financial results for Q4 and full year 2025, with Q4 adjusted EPS increasing but full year adjusted EPS declining. Crucially, the company issued full year 2026 guidance for adjusted diluted EPS of $5.00 - $5.25, which is significantly lower than the $6.08 achieved in full year 2025. This lowered guidance, coupled with a strategic shift to focus on innovative radiodiagnostics and explore alternatives for radiotherapeutic assets, represents a material change in the company's financial outlook and operational strategy. While the $100 million share repurchase and pipeline advancements are positive, the reduced earnings guidance is likely to be the primary driver of investor sentiment.
At the time of this filing, LNTH was trading at $68.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5B. The 52-week trading range was $47.25 to $111.29. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.